Nuwellis, Inc.

NasdaqCM NUWE

Nuwellis, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024

Nuwellis, Inc. Operating Cash Flow is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating cash flow is cash generated from the company’s regular business operations.

Nuwellis, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -16.21 M, a 5.16% change year over year.
Nuwellis, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -17.10 M.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqCM: NUWE

Nuwellis, Inc.

CEO	Mr. Nestor Jaramillo Jr.
IPO Date	Feb. 16, 2012
Location	United States
Headquarters	12988 Valley View Road
Employees	59
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Key trends

Past 5 years